- Trials with a EudraCT protocol (352)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
352 result(s) found for: Directed therapy.
Displaying page 1 of 18.
EudraCT Number: 2006-004160-32 | Sponsor Protocol Number: 004670 | Start Date*: 2006-11-15 |
Sponsor Name:Queen Mary's University of London | ||
Full Title: Biological effects of Goal Directed Therapy in surgical patients | ||
Medical condition: Post-operative complications in patients who undergo major surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-005412-21 | Sponsor Protocol Number: DOBU-Whipple | Start Date*: 2021-04-06 |
Sponsor Name:UZ Gent | ||
Full Title: Effect of dobutamine on hepatic blood flow during goal-directed hemodynamic therapy. | ||
Medical condition: Evaluating hepatic blood flow and caval & portal vein pressures during goal-directed hemodynamic therapy in patients undergoing pancreaticoduodenectomy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004139-66 | Sponsor Protocol Number: AGO/2018/006 | Start Date*: 2019-04-11 |
Sponsor Name:Ghent University Hospital | ||
Full Title: Effect of norepinephrine infusion on hepatic blood flow during goal-directed hemodynamic therapy. | ||
Medical condition: hepatic blood flow hepatic vascular pressures | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-006135-12 | Sponsor Protocol Number: BalaCriCo | Start Date*: 2008-12-19 |
Sponsor Name:Charité- University Medicine Berlin | ||
Full Title: Balanced crystalloids versus balanced colloids within a goal-directed hemodynamic protocol in patients undergoing gynaecological tumor resection. Balancierte Kristalloide versus balancierte Kolloi... | ||
Medical condition: The drugs Jonsteril and Volulyte6% will be investigated in female patients undergoing a tumor reduction operation. The study population will be female patients with metastatic ovarian carcinoma. Th... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-002333-21 | Sponsor Protocol Number: 1 | Start Date*: 2006-07-28 |
Sponsor Name:Allgemeines Krankenhaus Wien, Medizinische Un iversität Wien [...] | ||
Full Title: Intraoperative Goal-Directed Fluid Therapy in Lean and Obese Patients | ||
Medical condition: Hemodynamics in obese patients differ from lean patients: Obese patients have a higher cardiac output, the absolute amount of their intravascular volume is increased, as is the intracellular volume... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-005145-51 | Sponsor Protocol Number: 13-152 | Start Date*: 2015-09-18 |
Sponsor Name:Maastricht University Medical Centre | ||
Full Title: A randomised controlled multicenter trial comparing ultrasound-accelerated catheter-directed thrombolysis, combined with standard anticoagulant therapy, with standard anticoagulant therapy alone, f... | ||
Medical condition: Acute primary iliofemoral deep vein thrombosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2005-004486-42 | Sponsor Protocol Number: CaVenT | Start Date*: 2006-01-03 |
Sponsor Name:Eastern Norway Regional Health Authority [...] | ||
Full Title: Catheter-directed Venous Thrombolysis (CaVenT) in Acute Iliofemoral Vein Thrombosis - an open Randomized, Controlled, Clinical Trial | ||
Medical condition: Acute ilio-femoral vein thrombosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005732-29 | Sponsor Protocol Number: MOM-M281-011 | Start Date*: 2021-11-19 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generali... | |||||||||||||
Medical condition: Myasthenia gravis (MG). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003679-40 | Sponsor Protocol Number: BEV-CCI-779-GBM-02 | Start Date*: 2008-09-03 | |||||||||||
Sponsor Name:Rigshospitalet | |||||||||||||
Full Title: A phase II study of temsirolimus and bevacizumab in recurrent glioblastoma multiforme | |||||||||||||
Medical condition: Glioblastoma multiforme and progression after prior VEGF-directed therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000377-40 | Sponsor Protocol Number: MST-188-07 | Start Date*: 2014-11-13 | |||||||||||
Sponsor Name:Mast Therapeutics, Inc. | |||||||||||||
Full Title: Evaluation of MST-188 in Acute Lower Limb Ischemia: A Phase 2 Randomized Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial Evaluating the Safety and Efficacy Of MST-188 in Subjects with... | |||||||||||||
Medical condition: Acute Lower Limb Ischemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003061-38 | Sponsor Protocol Number: NL82555.100.22 | Start Date*: 2023-05-02 |
Sponsor Name:Sint Antonius Ziekenhuis | ||
Full Title: Genotype-gUIded cLopidogrel monoTherapY (POPular GUILTY) | ||
Medical condition: Non-ST elevation acute coronary syndrome (coronary artery disease) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2008-001712-21 | Sponsor Protocol Number: ESBA105CRD02 | Start Date*: 2009-03-05 | |||||||||||
Sponsor Name:Delenex Therapeutics AG | |||||||||||||
Full Title: A double-blind, randomised placebo-controlled Phase I/IIa study to investigate the safety, tolerability and efficacy on pain of intra-articular ESBA105 applied to patients with severely painful os... | |||||||||||||
Medical condition: Osteoarthritis of the knee | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000579-18 | Sponsor Protocol Number: IMMU-132-11 | Start Date*: 2022-06-20 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors | |||||||||||||
Medical condition: Metastatic Solid Tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001686-28 | Sponsor Protocol Number: 101.321-13/07 | Start Date*: 2008-10-16 | |||||||||||
Sponsor Name:Universität Wuerzburg | |||||||||||||
Full Title: Prospectively randomized phase III study of an individualized sensitivity-directed combination chemotherapy versus DTIC as first-line treatment in stage IV metastatic melanoma | |||||||||||||
Medical condition: metastastic malignant melanoma (AJCC stage IV), not previously treated with chemotherapy (chemonaive) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000380-13 | Sponsor Protocol Number: CP-MGAH22-04 | Start Date*: 2015-09-02 | |||||||||||||||||||||
Sponsor Name:MacroGenics, Inc. | |||||||||||||||||||||||
Full Title: A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 The... | |||||||||||||||||||||||
Medical condition: Metastatic or Locally Advanced HER2-positive Breast Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) PT (Completed) CZ (Completed) AT (Completed) FI (Completed) ES (Completed) DK (Completed) FR (Ongoing) PL (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-000591-33 | Sponsor Protocol Number: BRD/06/009 | Start Date*: 2006-05-10 | ||||||||||||||||
Sponsor Name:University College London | ||||||||||||||||||
Full Title: A Phase II study of Gemcitabine and Bexarotene (GemBex) in the treatment of cutaneous T-cell lymphoma | ||||||||||||||||||
Medical condition: Relapsed/refractory cutaneous T-cell lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-003217-41 | Sponsor Protocol Number: AGMT_ERCC1 | Start Date*: 2012-05-23 | ||||||||||||||||
Sponsor Name:Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH | ||||||||||||||||||
Full Title: Biomarker directed treatment in metastatic colorectal cancer | ||||||||||||||||||
Medical condition: This pilot study is being mounted to assess whether treatment assignment by ERCC-1 gene expression status suggests better clinical results from historical experience in mCRC. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-001673-14 | Sponsor Protocol Number: CCTL019A2205B | Start Date*: 2015-10-06 | ||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
Full Title: Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy | ||||||||||||||||||
Medical condition: All patients who have been treated with chimeric antigen receptor (CAR) T-cell therapy in the context of a prior Novartis sponsored or supported study for any indication. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) NO (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned) GB (GB - no longer in EU/EEA) SE (Trial now transitioned) FI (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005337-31 | Sponsor Protocol Number: CHUB-fluides | Start Date*: 2015-02-23 | |||||||||||
Sponsor Name:CHU Brugmann | |||||||||||||
Full Title: Crystalloids or colloids for goal-directed fluid therapy with closed-loop assistance in major surgery? | |||||||||||||
Medical condition: Major abdominal surgery, by laporotomy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005276-14 | Sponsor Protocol Number: RGCH004 | Start Date*: 2016-06-03 | |||||||||||
Sponsor Name:Sykehuset Østfold HF | |||||||||||||
Full Title: Prolonging the response by low-dose Rituximab maintenance therapy in immune thrombocytopenia: a randomized placebo-controlled trial- the PROLONG trial. | |||||||||||||
Medical condition: Immune thrombocytopenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) DK (Completed) FR (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
